Prevalent Pseudoprogression and Pseudoresidue in Patients With Rectal Cancer Treated With Neoadjuvant Immune Checkpoint Inhibitors.
Xie Y, Lin J, Zhang N, Wang X, Wang P, Peng S, Li J, Wu Y, Huang Y, Zhuang Z, Shen D, Zhu M, Liu X, Liu G, Meng X, Huang M, Yu H, Luo Y.
Xie Y, et al. Among authors: luo y.
J Natl Compr Canc Netw. 2023 Feb;21(2):133-142.e3. doi: 10.6004/jnccn.2022.7071.
J Natl Compr Canc Netw. 2023.
PMID: 36791752